Fate Therapeutics Q3 cash $225.7M; UK/EU approval for FT819; first SSc patient treated

FATE THERAPEUTICS INC

2025-Q3 EPS reported -$0.88 vs consensus -$0.30 ▼ miss (-196.4%)

Cash, cash equivalents & investments $225.7M; projected runway through year-end 2027.
Total revenue $1.7M from Ono collaboration; operating expenses $36.5M incl. $4.9M SBC.
Received UK MHRA and EU EMA authorization to activate ex-US sites for FT819 in autoimmune disease.
First systemic sclerosis patient treated in Phase 1 with fludarabine-free conditioning; no notable AEs.
First patient (stage IV CRC) treated with FT836 MICA/B-targeted CAR T with no conditioning chemotherapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.